Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorized
  2. c-icon icon-chevron-right
August 4, 2013

GW Pharmaceuticals reports results from multiple sclerosis spasticity study of Sativex

Biopharmaceutical company GW Pharmaceuticals has reported results from a multiple sclerosis (MS) spasticity study confirming Sativex has no long-term negative effect on cognition.

MS

Biopharmaceutical company GW Pharmaceuticals has reported results from a multiple sclerosis (MS) spasticity study confirming Sativex has no long-term negative effect on cognition.

Conducted in 121 patients with spasticity due to MS, the 12-month, multicentre, double-blind, randomised placebo-controlled study confirmed the reassuring safety profile of Sativex in addition to providing further evidence of long-term efficacy.

GW R&D director Dr Stephen Wright said that positive and wholly reassuring results were demonstrated in the 12-month placebo-controlled study in patients with MS spasticity.

"We have now shown that Sativex does not impair cognition either in short-term or in long-term use in well designed, randomised, placebo controlled clinical trials," Wright added.

"These data not only confirm the good tolerability of Sativex in long-term use but also provide further evidence of efficacy consistent with that seen in previous shorter duration clinical trials."

"These data not only confirm the good tolerability of Sativex in long-term use but also provide further evidence of efficacy consistent with that seen in previous shorter duration clinical trials."

The study was conducted as part of a post-approval commitment by the UK regulatory authority, the Medicines and Healthcare products Regulatory Agency (MHRA), to assess the long-term adverse effects of Sativex on cognitive function or mood.

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials

The study’s primary endpoint was the change in cognitive function as assessed by the total Paced Auditory Serial Addition Test (PASAT) score from baseline to end of treatment. Mood was assessed by the Beck Depression Inventory-II.

Confirming nil evidence of long-term cognitive impairment in patients taking Sativex against placebo, a slight improvement in the PASAT score from the beginning to the end of the study in both the Sativex and placebo groups was observed.

Furthermore, the mood change over the 12-month period was nearly identical in the Sativex and the placebo group, confirming no untoward effect on mood.

The parallel group, placebo-controlled study confirmed no untoward effect on mood by demonstrating nearly identical mood change over the 12-month period in the Sativex and the placebo group.

The key efficacy secondary endpoints – global impression of change scores as assessed by the patient, physician and carer – demonstrated in favour of Sativex.


Image: Photomicrograph of a demyelinating MS-lesion. Klüver-Barerra-Stain. Original Magnification 10x. Photo courtesy of Marvin 101.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU